A Single-arm, Open-label, Single-center, Multiple-dose Early Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of KSD-201 in Patients with Advanced Clear Cell Renal Cell Carcinoma
Latest Information Update: 06 Dec 2024
Price :
$35 *
At a glance
- Drugs KSD 201 (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Sponsors Kousai Bio
- 06 Dec 2024 New trial record